Giuseppe Bruno | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Mild behavioral impairment: Ethical, methodological and clinical reflections	NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS	2016
Sundowning in dementia. clinical relevance, pathophysiological determinants, and therapeutic approaches	FRONTIERS IN MEDICINE	2016
How to deal with missing longitudinal data in cost of illness analysis in Alzheimer's disease-suggestions from the GERAS observational study	BMC MEDICAL RESEARCH METHODOLOGY	2016
Identifying factors of activities of daily living important for cost and caregiver outcomes in Alzheimer's disease	INTERNATIONAL PSYCHOGERIATRICS	2016
PRNP P39L variant is a rare cause of frontotemporal dementia in Iialian population	JOURNAL OF ALZHEIMER'S DISEASE	2016
Progression of extrapyramidal signs in Alzheimer's disease. clinical and neuropathological correlates	JOURNAL OF ALZHEIMER'S DISEASE	2016
Neuropsychological predictors of rapidly progressive Alzheimer's disease	ACTA NEUROLOGICA SCANDINAVICA	2015
Sorl1 gene is associated with the conversion from mild cognitive impairment to alzheimer's disease.	JOURNAL OF ALZHEIMER'S DISEASE	2015
Determinants of societal costs in alzheimer's disease. geras study baseline results	ALZHEIMER'S & DEMENTIA	2015
Cognitive reserve and the risk for alzheimer's disease. a longitudinal study	NEUROBIOLOGY OF AGING	2015
Sociodemographic and clinical changes over time of individuals evaluated for cognitive disturbances: good or bad news?	JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION	2015
From evidence to action. promoting a multidimensional approach to mild cognitive impairment	JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION	2015

ERC

LS5_11

Interessi di ricerca

Neurologia cognitiva; epidemiologia, genetica, clinica e neurofarmacologia della malattia di Alzheimer e altre demenze e delle malattie extrapiramidali con particolare riferimento alla sperimentazione di nuove procedure diagnostiche e terapeutiche (studi di neurofarmacologia clinica di fase 2-3-4) disturbi neuropsichiatrici; prevenzione dei disturbi cognitivi; nuove metodiche di somministrazione farmacologica e relative strategie terapeutiche in accordo con GCP.